This upregulation occurs in both BRCA1/2-mutated and -WT cells, but only affects PARPi sensitivity in BRCA1/2-mutated cells, further supporting our previous findings that ALDH1A1 inhibitor can only be used to treat HR-deficient ovarian cancer cells in combination with PARPi12. This evidence concerns the gene ALDH1A1 and ovarian cancer.